Five to eight years of experience as a technical writer, preferably in industry (software, hardware, biotech)…. $75 an hour
From International Programming & Systems Inc. – Thu, 22 Sep 2016 04:52:31 GMT – View all San Diego jobs
B.S./M.S./ PhD in Engineering, Bioengineering, Biotechnical Engineering, Industrial or Manufacturing Engineering, or MS/PhD in Materials Science or Physical…From Illumina, Inc. – Thu, 22 Sep 2016 02:31:22 GMT – View all San Diego jobs
Experience in biotech is a plus. Work as part of Agile scrum teams to design, implement, and test the instrument control software that powers our industry…From Illumina, Inc. – Mon, 26 Sep 2016 08:48:42 GMT – View all San Diego jobs
Biotech or Pharmaceutical:. ERP implementation experience preferred. Excellent analytical skills with demonstrated experience utilizing financial data,…From Indeed – Wed, 21 Sep 2016 23:16:36 GMT – View all San Diego jobs
17-year-old Digital Marketing agency is seeking to hire new inside sales consultants. The company provides Social Media, Web Marketing, SEO and other online marketing solutions to businesses throughout the USA.
We especially are seeking to hire energ […
Minimum 5 years experience in similar position; This position is located in our corporate office in San Diego’s biotech community….
From Indeed – Wed, 21 Sep 2016 18:35:09 GMT – View all San Diego jobs
Demonstrated expertise in multiple statistical areas by having 4 years direct data management experience, with at least 3 years experience in a pharmaceutical,…From Prometheus Laboratories – Wed, 21 Sep 2016 16:00:58 GMT – View all San Diego jobs
Newly formed public-private alliance is working to create an arsenal of vaccines to prevent future epidemics from becoming public health emergencies
REDWOOD CITY, Calif., Sept. 21, 2016 /PRNewswire/ — PaxVax today announced its President and CEO, Nima Farzan, has been invited to join the interim board of the Coalition for Epidemic Preparedness Innovations (CEPI) as the Biotechnology Innovation Organization (BIO) delegate. CEPI is a new, public-private alliance designed to speed the development of new vaccines to prevent and contain global epidemics. Sparked by recent gaps in vaccine preparedness for outbreaks of Zika and Ebola, CEPI aims to facilitate the creation of an arsenal of vaccines to prevent diseases such as these from becoming public health emergencies in the future.
“PaxVax is committed to developing and delivering vaccines that address global public health threats. In joining the CEPI leadership, I look forward to continue pursuing innovative efforts aimed to prepare against future pandemics,” said Farzan. “As biotech companies have both the expertise and responsibility to take part in this cause, I am thrilled to join CEPI’s visionary team of experts in the global fight to protect against infectious diseases.”
CEPI was founded by the Wellcome Trust, the Bill and Melinda Gates Foundation, the World Economic Forum and the governments of Norway and India. The organization will finance, coordinate and facilitate the development of vaccines for potential global threats before outbreaks begin. Farzan joins CEPI’s board of global leaders from academia, government, non-profits and industry, gathered to shape an informed, collaborative approach to ensure vaccines are available for all populations who need them.
“We have seen in recent outbreaks that when working alone, industry players face barriers to vaccine development,” Farzan said. “CEPI’s collaborative approach is vital in taking on global health threats. I am proud to serve on its board among leaders forging a unified response to pandemics.”
Farzan has been President and CEO of PaxVax since 2015 and previously served as Chief Operating Officer from 2011. He has extensive biopharmaceutical experience, most recently providing leadership at PaxVax in the advancement of a vaccine for cholera from research and development through to approval by the U.S. Food and Drug Administration.
PaxVax develops, manufactures and commercializes innovative specialty vaccines against infectious diseases present and emerging in the developing world. PaxVax has licensed vaccines for typhoid fever (Vivotif®) and cholera (Vaxchora™), and vaccines at various stages of research and clinical development for adenovirus, anthrax, hepatitis A, HIV, and Zika. PaxVax is focused on traditionally overlooked markets such as travel, and as part of its social mission, PaxVax is also working to make its vaccines available to broader populations most affected by these diseases. PaxVax is headquartered in Redwood City, California and maintains research and development and Good Manufacturing Practice (GMP) facilities in San Diego, California and Bern, Switzerland and other operations in Bermuda and Europe. More information is available at www.PaxVax.com.
A core tenet of Xconomy—and the reason behind our broad coverage across information technology, life sciences, energy, and more—is that the most interesting and important innovations often…
[[Click headline to continue reading.]]
SAN FRANCISCO, Sept. 21, 2016 /PRNewswire/ — Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the following upcoming investor conferences:
- LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
September 28, 2016, 9:30 AM ET
Lotte New York Palace, New York
- Jefferies 2016 Gene Editing/Therapy Summit
October 11, 2016, 12:00 PM ET
Jefferies Conference Center, New York
To access live webcasts of the presentations, please visit the Events & Presentations page within the Investors & News section of the Audentes website. Replays of live webcasts will be available on the Audentes website for approximately 30 days following the conference.
About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases. We have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.
For more information regarding Audentes, please visit www.audentestx.com.
Thomas Soloway, CFO
SOURCE Audentes Therapeutics, Inc.